Clinical uses of benzodiazepines. Focus on: benzodiazepines and anxiety disorders

被引:0
|
作者
Bossini, L. [1 ]
Borghini, E. [1 ]
Fagiolini, A. [1 ]
机构
[1] Univ Siena, Dipartimento Med Mol Sviluppo, Sez Psichiatria, Siena, Italy
来源
JOURNAL OF PSYCHOPATHOLOGY | 2013年 / 19卷 / 03期
关键词
Benzodiazepines; Anxiety; Anxiety disorders;
D O I
暂无
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Benzodiazepines (BDZs) are usually safe and well-tolerated medications, which may be effectively prescribed in Anxiety Disorders and several other conditions requiring an anxiolytic and hypnotic therapeutic effect. Most often, BDZs should be considered as a complementary, rather than alternative, treatment to antidepressants such as SSRIs and SNRIs or to psychotherapies. Nonetheless, BDZs my be very useful tools both in the acute treatment phase, due to their ability to control anxious symptoms before the antidepressants start working, and in the continuation-maintenance treatment phase, as augmenting agents. BDZ have proven very effective in panic disorder, generalized anxiety and, even if to a lower degree, in social phobia. BDZ role in obsessive compulsive disorder and post traumatic stress disorder is not as strong but these medications may be useful for several patients with those diseases. BDZ are not devoid of side effects and risks such as tolerance and dependence. However, those risks may be reduced when BDZ are not used at high doses for long periods of time, when the choice of the specific compound is driven by an accurate evaluation of the specific pharmacokinetic properties and when patients at high risk of dependence are not prescribed these compounds, especially at high doses and for long periods of time.
引用
收藏
页码:272 / 286
页数:15
相关论文
共 50 条
  • [31] Evolution of the practices of prescription of benzodiazepines. What about their association?
    Dejean, C.
    Chabaud, F.
    Pigeot, E.
    Bouet, R.
    Richard, D.
    Levy-Chavagnat, D.
    EUROPEAN PSYCHIATRY, 2014, 29 (08) : 655 - 655
  • [32] Clinical characteristics associated with benzodiazepines' use in mood, anxiety and psychotic spectrum disorders
    De Carlo, V.
    Grancini, B.
    Vismara, M.
    Arici, C.
    Cirnigliaro, G.
    Altamura, A. C.
    Dell'Osso, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S89 - S90
  • [33] Process development of oxazino- and thiazino- benzodiazepines.
    Grimm, JS
    Dyatkin, AB
    Gelormini, AM
    Hoekstra, WJ
    Liu, FQ
    Maryanoff, BE
    Maryanoff, CA
    Matthews, JM
    Poulter, BL
    Sorgi, KL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 223 : B181 - B181
  • [34] DRUG-THERAPY - USE OF BENZODIAZEPINES IN ANXIETY DISORDERS
    SHADER, RI
    GREENBLATT, DJ
    NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (19): : 1398 - 1405
  • [35] Benzodiazepines for the long-term treatment of anxiety disorders?
    Tibrewal, Prashant
    Looi, Jeffrey C. L.
    Allison, Stephen
    Bastiampillai, Tarun
    LANCET, 2021, 398 (10295): : 119 - 120
  • [38] Pilot psychotherapy program for the deprescription of benzodiazepines for anxiety disorders
    Fontanet, Antonieta Also
    Kostov, Belchin
    Areu, Jaume Benavent
    Martinez, Montserrat Pinyol
    Momblona, Josep Miquel Sotoca
    Hernandez, Antoni Benabarre
    Siso-Almirall, Antoni
    ANSIEDAD Y ESTRES-ANXIETY AND STRESS, 2022, 28 (01): : 71 - 77
  • [39] Systematic review of benzodiazepines for anxiety disorders in late life
    Gupta, Aarti
    Bhattacharya, Gargi
    Farheen, Syeda Arshiya
    Funaro, Melissa
    Balasubramaniam, Meera
    Young, Juan
    Tampi, Deena J.
    Tampi, Rajesh R.
    ANNALS OF CLINICAL PSYCHIATRY, 2020, 32 (02) : 114 - 127
  • [40] Anxiety and panic disorders: Correct usage and discontinuation of benzodiazepines
    VanMoffaert, M
    ACTA THERAPEUTICA, 1996, 22 (01) : 13 - 22